Sebastian A. Brunemeier

Our drug will target mitochondria – the powerhouse of the cell – to generate heat. This approach has been proven to fully reverse obesity and type 2 diabetes in animals. However, therapeutic application for humans was impossible, because mitochondrial heat production could only be induced by highly artificial methods with side effects. This changed after our recent breakthrough discovery of the protein that mitochondria naturally use to generate heat. We have developed a unique high-throughput drug discovery platform to identify compounds that selectively activate this target protein, without side effects. For decades people have wanted a drug that burns calories like exercise does. We are realizing this dream at Equator Therapeutics.

Clinical stage biotechnology company developing a new class of cognitive enhancing small molecules targeting cognitive decline. Our first drug candidate RIV-5061 targets the treatment of Mild Cognitive Impariment. We are in the process of raising funding for Phase 1/1b clinical trials.

At LongGame, we are dedicated to funding radical lifespan extension for everyone. We invest in companies aiming for significant advancements in life extension, our focus is on scalable solutions that benefit society as a whole, ensuring longevity is accessible to all, not just a select few. Integrity and evidence guide our investments, as we prioritise companies with strong ethical foundations and robust scientific backing. Join us in pioneering a future where extended, healthy lifespans are a reality for all!

Geneva College of Longevity Science (GCLS) is the first institute of higher education focusing entirely on longevity science. GCLS Executive Master of Science in Longevity (EMSc Longevity) is a distance learning masters programme that covers a wide range of topics related to the science and practice of longevity. It aims to empower professionals in the space by providing them with opportunities to deepen their knowledge through academic education, thereby enhancing their credibility and authenticity within the field. Its curriculum has been designed for practitioners seeking to deepen their comprehension of longevity interventions and financial and policy decision-makers aiming to acquire the expertise necessary for informed future decisions. Students attend the programme via GCLS’ online study platform, which offers them the possibility to continue their education in the most flexible and effective manner. The programme adopts a comprehensive, multidisciplinary approach, covering state-of-art scientific findings associated with ageing, health, and longevity. It serves as a catalyst for elevating professional excellence and prepares graduates for leadership roles in the landscape of longevity-related work.

Picus Capital is an early-stage technology investment firm with a long-term investment philosophy. We work together with daring technology companies to build successful, global companies challenging the status quo and shaping tomorrow